129 results on '"Riely, G.J."'
Search Results
2. COVID-19 in patients with lung cancer
3. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
4. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
5. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
6. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
7. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
8. MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC
9. P2.09-14 Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations
10. P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers
11. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
12. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers
13. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
14. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
15. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
16. 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
17. 1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
18. EP08.02-171 PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)
19. LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
20. 1392TiP Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
21. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
22. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
23. 1218P Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
24. 474P Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE
25. 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
26. 1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes
27. 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
28. 8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
29. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
30. 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
31. O1–133 - Crizotinib vs. Pemetrexed or Docetaxel in Advanced Alk+ Non-Small Cell Lung Cancer: Subgroup Analysis in Profile 1007
32. O1–132 - Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)
33. P2.14B.03 A Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients with Advanced Thymoma and Thymic Carcinoma
34. Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
35. Investigation of patterns of nodal metastases in BRAF mutant lung cancer
36. Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
37. Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
38. 3LBA Late Breaking - KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
39. PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators
40. 107O - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
41. 1380PD - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
42. 1396P - Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
43. Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation?
44. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
45. Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy?
46. Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1
47. Dabrafenib in Patients with Braf V600E-Mutant Advanced Non-Small Cell Lung Cancer (Nsclc): a Multicenter, Open-Label, Phase Ii Trial (Brf113928)
48. A Phase Ib Dose-Escalation Study of the Hsp90 Inhibitor Snx-5422 and Erlotinib in Patients with Egfr-Mutant Lung Cancer and Acquired Resistance to Egfr Tyrosine Kinase Inhibitors
49. Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study
50. Prospective Molecular Evaluation of Small Cell Lung Cancer (Sclc) Utilizing the Comprehensive Mutation Analysis Program (Map) at Memorial Sloan Kettering Cancer Center (Mskcc)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.